Analysts See $-0.17 EPS for Rigel Pharmaceuticals, Inc. (RIGL)

April 20, 2018 - By Richard Conner

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) LogoInvestors sentiment increased to 2.06 in 2017 Q4. Its up 0.67, from 1.39 in 2017Q3. It is positive, as 14 investors sold Rigel Pharmaceuticals, Inc. shares while 18 reduced holdings. 22 funds opened positions while 44 raised stakes. 127.13 million shares or 21.87% more from 104.32 million shares in 2017Q3 were reported.
5,619 were reported by Prelude Mgmt Ltd Limited Liability Company. Price T Rowe Associate Md has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Ghost Tree Cap Limited Liability reported 825,000 shares. Baker Bros Limited Partnership has invested 0.08% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Moreover, State Of Wisconsin Board has 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 85,000 shares. Moreover, First Personal has 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 1,600 shares. Ontario – Canada-based Manufacturers Life Insurance Communications The has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Eam Ltd Llc reported 475,613 shares. Morgan Stanley owns 309,827 shares for 0% of their portfolio. Bnp Paribas Arbitrage accumulated 0% or 30,038 shares. Utd Serv Automobile Association holds 356,472 shares. Palo Alto Investors Lc holds 3.94 million shares or 0.66% of its portfolio. Amalgamated State Bank reported 0% stake. State Street Corp stated it has 3.99M shares. The New York-based Jpmorgan Chase & has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL).

Analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $-0.17 EPS on May, 1.They anticipate $0.04 EPS change or 30.77 % from last quarter’s $-0.13 EPS. After having $-0.18 EPS previously, Rigel Pharmaceuticals, Inc.’s analysts see -5.56 % EPS growth. The stock decreased 2.22% or $0.09 during the last trading session, reaching $3.97. About 5.53 million shares traded or 120.35% up from the average. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 9.91% since April 20, 2017 and is uptrending. It has underperformed by 1.64% the S&P500.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Among 6 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals had 12 analyst reports since November 6, 2017 according to SRatingsIntel. On Friday, January 19 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Wednesday, March 7. On Monday, December 11 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by BMO Capital Markets on Tuesday, November 7. The firm has “Buy” rating by H.C. Wainwright given on Monday, November 6. The rating was maintained by H.C. Wainwright on Friday, February 2 with “Buy”. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Tuesday, April 3. H.C. Wainwright has “Buy” rating and $6.7 target. Piper Jaffray initiated Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Thursday, December 21 with “Buy” rating. The firm earned “Buy” rating on Tuesday, March 6 by Cantor Fitzgerald. Jefferies maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Wednesday, April 4. Jefferies has “Buy” rating and $500 target.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $585.06 million. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: